Bellevue Group AG Has $81.27 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

Bellevue Group AG reduced its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 3.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,097,848 shares of the medical research company's stock after selling 36,228 shares during the period. Edwards Lifesciences makes up approximately 1.6% of Bellevue Group AG's holdings, making the stock its 17th largest holding. Bellevue Group AG owned approximately 0.19% of Edwards Lifesciences worth $81,274,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of EW. Benjamin Edwards Inc. boosted its holdings in shares of Edwards Lifesciences by 25.1% in the 4th quarter. Benjamin Edwards Inc. now owns 19,168 shares of the medical research company's stock worth $1,419,000 after acquiring an additional 3,844 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in Edwards Lifesciences in the fourth quarter worth $49,038,000. Aptus Capital Advisors LLC boosted its stake in Edwards Lifesciences by 25.8% in the fourth quarter. Aptus Capital Advisors LLC now owns 10,001 shares of the medical research company's stock worth $740,000 after purchasing an additional 2,052 shares in the last quarter. Aspire Growth Partners LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $237,000. Finally, Advanced Portfolio Management LLC acquired a new position in Edwards Lifesciences during the 4th quarter worth about $328,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Bernard J. Zovighian sold 6,164 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares of the company's stock, valued at approximately $4,106,859.33. This trade represents a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $69.81, for a total transaction of $663,195.00. Following the sale, the vice president now directly owns 47,206 shares in the company, valued at $3,295,450.86. This trade represents a 16.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 77,833 shares of company stock worth $5,611,023 over the last three months. Corporate insiders own 1.29% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on EW shares. Truist Financial dropped their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Piper Sandler upgraded shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $73.00 to $80.00 in a research report on Thursday, April 24th. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and increased their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Robert W. Baird boosted their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday, April 24th. Finally, Morgan Stanley raised their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $79.45.

Edwards Lifesciences Stock Down 0.2 %

Shares of EW traded down $0.17 on Tuesday, hitting $74.94. The company's stock had a trading volume of 2,378,625 shares, compared to its average volume of 5,019,167. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $44.05 billion, a price-to-earnings ratio of 10.75, a P/E/G ratio of 4.82 and a beta of 1.12. The firm's fifty day moving average price is $71.30 and its 200-day moving average price is $71.41. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business's quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.66 earnings per share. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.